Lisa Barroilhet, MD, discusses the role of PARP inhibitors in patients with ovarian cancer.
Lisa M. Barroilhet, MD
Advertisement
Articles by Lisa M. Barroilhet, MD
PARP inhibitors are the most commonly used targeted therapy for patients with recurrent ovarian cancer, and the indications for the use of these drugs have broadened in recent months.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
First-Line Niraparib Maintenance Yields Longer PFS in HRD-Positive vs HRD-Negative Optimally Debulked Ovarian Cancer
2
Dr Traina on Integrating T-DXd and Biomarkers Into Early-Stage HER2-Positive Breast Cancer Care
3
LITESPARK-022 PRO Data Further Support Adjuvant Belzutifan Plus Pembrolizumab in ccRCC
4
Dr Borgen on Matching Treatment to HER2 Biology in Early-Stage HER2-Positive Breast Cancer
5